Payment overview · 2025
General Payments
$251.57
6 reported records · 5 companies
Healthcare provider profile · identity verified
Vaishali Harshul Patel, MD
Allopathic & Osteopathic Physicians|Family Medicine · CADIZ, KY · NPI 1942437603
Verified facts
What the public records show
CMS Open Payments records show Vaishali Harshul Patel, MD received $251.57 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 49.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.54 | 26.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.54 | 9.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.61 | 7.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $17.88 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $251.57 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $65.54 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 75 |
| Gabapentin | Gabapentin | 308 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 308 | 47 |
| Lisinopril | Lisinopril | 305 | 83 |
| Omeprazole | Omeprazole | 240 | 54 |
| Losartan Potassium | Losartan Potassium | 236 | 58 |
| Eliquis | Apixaban | 218 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 61 |
| Ozempic | Semaglutide | 199 | 34 |
| Potassium Chloride | Potassium Chloride | 180 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 44 |
| Trazodone Hcl | Trazodone Hcl | 178 | 32 |
| Furosemide | Furosemide | 170 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 43 |
| Metformin Hcl | Metformin Hcl | 152 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 25 |
| Simvastatin | Simvastatin | 127 | 31 |
| Sertraline Hcl | Sertraline Hcl | 126 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 24 |
| Buspirone Hcl | Buspirone Hcl | 121 | 23 |
| Carvedilol | Carvedilol | 109 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 26 |
| Alprazolam | Alprazolam | 101 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 27 |
| Tramadol Hcl | Tramadol Hcl | 92 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 49 |
| Mirtazapine | Mirtazapine | 90 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 20 |
| Farxiga | Dapagliflozin Propanediol | 80 | 17 |
| Glipizide | Glipizide | 80 | 17 |
| Xarelto | Rivaroxaban | 80 | suppressed |
| Januvia | Sitagliptin Phosphate | 79 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 13 |
| Meloxicam | Meloxicam | 76 | 21 |
| Glimepiride | Glimepiride | 74 | 24 |
| Famotidine | Famotidine | 72 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | suppressed |
| Clonazepam | Clonazepam | 68 | 11 |
| Trulicity | Dulaglutide | 67 | suppressed |
| Atenolol | Atenolol | 66 | 18 |
| Jardiance | Empagliflozin | 66 | 13 |
| Risperidone | Risperidone | 66 | suppressed |
| Methylprednisolone | Methylprednisolone | 65 | 47 |
| Amoxicillin | Amoxicillin | 64 | 49 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 13 |
| Ibuprofen | Ibuprofen | 56 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 17 |
| Allopurinol | Allopurinol | 53 | 18 |
| Montelukast Sodium | Montelukast Sodium | 53 | 18 |
| Fluconazole | Fluconazole | 52 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 28 |
| Azithromycin | Azithromycin | 47 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 16 |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 12 |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 18 |
| Prednisone | Prednisone | 41 | 26 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 21 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Nystatin | Nystatin | 37 | 21 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 16 |
| Acyclovir | Acyclovir | 33 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Loperamide | Loperamide Hcl | 33 | 17 |
| Naproxen | Naproxen | 33 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 15 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Indapamide | Indapamide | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Humira Pen | Adalimumab | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 18 |
| Olanzapine | Olanzapine | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 19 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 13 |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $251.57 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, FANAPT, REXULTI, Senza | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error